These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 10786253)

  • 1. Doxazosin dropped from ALLHAT study.
    Miller JL
    Am J Health Syst Pharm; 2000 Apr; 57(8):718. PubMed ID: 10786253
    [No Abstract]   [Full Text] [Related]  

  • 2. Should patients with benign prostatic hypertrophy stop taking doxazosin in the light of the ALLHAT study?
    Cheng TO
    Int J Cardiol; 2006 Feb; 107(2):275-6. PubMed ID: 16412808
    [No Abstract]   [Full Text] [Related]  

  • 3. Doxazosin arm of the ALLHAT study discontinued: how equal are antihypertensive drugs? Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial.
    Messerli FH; Grossman E
    Curr Hypertens Rep; 2000 Jun; 2(3):241-2. PubMed ID: 10981155
    [No Abstract]   [Full Text] [Related]  

  • 4. Doxazosin for the management of hypertension: implications of the findings of the ALLHAT trial.
    Poulter N; Williams B
    Am J Hypertens; 2001 Nov; 14(11 Pt 1):1170-2. PubMed ID: 11724218
    [No Abstract]   [Full Text] [Related]  

  • 5. Operational aspects of terminating the doxazosin arm of The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Pressel SL; Davis BR; Wright JT; Geraci TS; Kingry C; Ford CE; Piller LB; Bettencourt J; Kimmel B; Lusk C; Parks H; Simpson LM; Nwachuku C; Furberg CD;
    Control Clin Trials; 2001 Feb; 22(1):29-41. PubMed ID: 11165421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health agencies update.
    JAMA; 2000 Apr; 283(15):1950. PubMed ID: 10789651
    [No Abstract]   [Full Text] [Related]  

  • 7. [Doxazosin and heart failure: a clinical conclusion is wanted].
    Järhult B; Lindahl SO
    Lakartidningen; 2003 Dec; 100(51-52):4328. PubMed ID: 14756102
    [No Abstract]   [Full Text] [Related]  

  • 8. [Misleading advertising claims about the indication of doxazosin (Cardura) for type 2 diabetes mellitus and hypertension].
    Janssen CA
    Ned Tijdschr Geneeskd; 2003 Jan; 147(3):135; author reply 135-6. PubMed ID: 12577776
    [No Abstract]   [Full Text] [Related]  

  • 9. Alpha-blockers and congestive heart failure: early termination of an arm of the ALLHAT trial.
    Vidt DG
    Cleve Clin J Med; 2000 Jun; 67(6):429-33. PubMed ID: 10860225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [ALLHAT Study: doxazosin arm is discontinued. Alpha blocker is less effective than a diuretic].
    Einecke D
    MMW Fortschr Med; 2000 Mar; 142(13):4-5. PubMed ID: 10783613
    [No Abstract]   [Full Text] [Related]  

  • 11. Doxazosin and congestive heart failure.
    Messerli FH
    J Am Coll Cardiol; 2001 Nov; 38(5):1295-6. PubMed ID: 11691497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. National Heart, Lung, and Blood Institute halts part of antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT).
    SoRelle R
    Circulation; 2000 Mar; 101(12):E9025. PubMed ID: 10736305
    [No Abstract]   [Full Text] [Related]  

  • 13. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group.
    JAMA; 2000 Apr; 283(15):1967-75. PubMed ID: 10789664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Doxazosin gastrointestinal therapeutic system: a clinical perspective.
    Mann SJ
    J Clin Hypertens (Greenwich); 2006 Mar; 8(3):207-8. PubMed ID: 16522999
    [No Abstract]   [Full Text] [Related]  

  • 15. Doxazosin and congestive heart failure.
    Sica DA
    Congest Heart Fail; 2002; 8(3):178-84. PubMed ID: 12045387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Established blood pressure drug wins out in a comparative study. In hypertension, a diuretic first!].
    Wepner U
    MMW Fortschr Med; 2003 Jan; 145(1-2):10-2. PubMed ID: 12638431
    [No Abstract]   [Full Text] [Related]  

  • 17. [Choice of antihypertensive agent--insignificant role of doxazosin (Alfadil). How are evidence-based recommendations implemented?].
    Gustafsson LL
    Lakartidningen; 2004 Jan; 101(3):228-9. PubMed ID: 14763097
    [No Abstract]   [Full Text] [Related]  

  • 18. [Misleading advertising claims about the indication of doxazosin (Cardura) for type 2 diabetes mellitus and hypertension].
    Hoogenberg K; van der Tuin J
    Ned Tijdschr Geneeskd; 2002 Nov; 146(44):2099-100. PubMed ID: 12448967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Are all antihypertensive agents equal? Cardiovascular events in hypertensive patients randomized to treatment with doxazosin or chlorthalidone. The ALLHAT study].
    Schillaci G; Verdecchia P
    Ital Heart J Suppl; 2000 Sep; 1(9):1215-7. PubMed ID: 11140297
    [No Abstract]   [Full Text] [Related]  

  • 20. Implications of discontinuation of doxazosin arm of ALLHAT. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
    Messerli FH
    Lancet; 2000 Mar; 355(9207):863-4. PubMed ID: 10752699
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.